Three doses provide sustained disease protection during first three years of life
MONDAY, Nov. 14 (HealthDay News) -- Three doses of pentavalent rotavirus vaccine (RV5) provide sustained protection against rotavirus disease, while two doses offer good protection, according to a study published online Nov. 14 in Pediatrics.
Margaret M. Cortese, M.D., from the Division of Viral Diseases at the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues measured the effectiveness of RV5 using case-control methodology. Rotavirus case-subjects included 402 children identified from the electronic immunization information system (IIS) of Minnesota, Georgia, and Connecticut, with gastroenteritis and the presence of rotavirus antigen in stool during any of three rotavirus seasons between 2007 and 2009. Rotavirus-negative controls included 825 children who met the eligibility criteria and were identified from the electronic IIS.
The investigators found that across control groups, immunization data sources, and states, vaccine effectiveness estimates for RV5 were similar. Among children aged 8 months or older, vaccine effectiveness point estimates for three versus zero doses were 89 to 94 percent, and among children aged 24 months or older the estimates were 86 to 92 percent. The vaccine effectiveness was 90 percent or more for two doses among children aged 8 months or older, and 66 percent for one dose in children aged 6 weeks to 5 months.
"Three doses of RV5 provide sustained protection against rotavirus disease in U.S. children. Two RV5 doses also seem to provide good protection," the authors write.
Abstract
Full Text (subscription or payment may be required)